{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:48:21Z","timestamp":1760708901453},"reference-count":35,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.3927","type":"journal-article","created":{"date-parts":[[2015,8,31]],"date-time":"2015-08-31T18:09:47Z","timestamp":1441044587000},"page":"2101-2108","source":"Crossref","is-referenced-by-count":11,"title":["Enhanced Steroid Therapy in Adult Minimal Change Nephrotic Syndrome: A Systematic Review and Meta-analysis"],"prefix":"10.2169","volume":"54","author":[{"given":"Lingfei","family":"Zhao","sequence":"first","affiliation":[{"name":"Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congcong","family":"Wu","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianghua","family":"Chen","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Broyer M, Meyrier A, Niaudet P, Habib R. Minimal changes and focal segmental glomerular sclerosis. In: Oxford Textbook of Clinical Nephrology. Vol. 1. Cameron S, Davison AM, Gr&uuml;nfeld JP, Kerr D, Ritz E, Eds. Oxford University Press, Oxford, 1992: 298-339."},{"key":"2","unstructured":"2. Nachman PH, Jennette JC, Falk RJ. Primary glomerular diseases. In: Brenner and Rector's The Kidney. 8th Ed. Brenner BM, Ed. W.B. Saunders, Philadelphia, 2008: 995-1000."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Bonilla-Felix M, Parra C, Dajani T, et al. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney Int 55: 1885-1890, 1999.","DOI":"10.1046\/j.1523-1755.1999.00408.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fuijimi S. Corticosteroid responsiveness and frequency of relapse in adult-incipient minimal change nephrotic syndrome. Am J Kidney Dis 39: 503-512, 2002.","DOI":"10.1053\/ajkd.2002.31400"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: Clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2: 445-453, 2007.","DOI":"10.2215\/CJN.03531006"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Li X, Li H, Chen J, et al. Tacrolimus as a corticosteroid-sparing agent for adults with corticosteroid-dependent minimal change nephrotic syndrome. Nephrol Dial Transplant 23: 1919-1925, 2008.","DOI":"10.1093\/ndt\/gfm637"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Palmer SC, Nand K, Strippoli GF. Interventions for minimal change disease in adults with nephrotic syndrome. Cochrane Database Syst Rev: CD001537, 2008.","DOI":"10.1002\/14651858.CD001537.pub4"},{"key":"8","unstructured":"8. Wells GA, Shea B, O'Connell D, et al. Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. In: Department of Epidemiology and Commuunity Medicine, University of Ottawa [Internet] [cited 2010 Sep 3]. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Matsumoto H, Nakao T, Okada T, et al. Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome. Intern Med 43: 668-673, 2004.","DOI":"10.2169\/internalmedicine.43.668"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Eguchi A, Takei T, Yoshida T, Tsuchiya K, Nitta K. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome. Nephrol Dial Transplant 25: 124-129, 2010.","DOI":"10.1093\/ndt\/gfp422"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Li XY, Tian J, Wu J, et al. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study. Clin Ther 31: 741-750, 2009.","DOI":"10.1016\/j.clinthera.2009.04.011"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Fukudome K, Fujimoto S, Sato Y, Kitamura K. Comparison of the effects of intravenous methylprednisolone pulse versus oral prednisolone therapies on the first attack of minimal-change nephrotic syndrome in adults. Nephrology 17: 263-268, 2012.","DOI":"10.1111\/j.1440-1797.2011.01544.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Imbasciati E, Gusmano R, Edefonti A, et al. Controlled trial of methylprednisolone pulses and low dose oralprednisone for the minimal change nephrotic syndrome. Br Med J 291: 1305-1308, 1985.","DOI":"10.1136\/bmj.291.6505.1305"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yeung CK, Wong KL, Ng WL. Intravenous methylprednisolone pulse therapy in minimal change nephrotic syndrome. Aust N Z J Med 13: 349-351, 1983.","DOI":"10.1111\/j.1445-5994.1983.tb04479.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shinzawa M, Yamamoto R, Nagasawa Y, et al. Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort study. Clin J Am Soc Nephrol 9: 1040-1048, 2014.","DOI":"10.2215\/CJN.12331213"},{"key":"16","unstructured":"16. Health Products and Food Branch. Clinical safety data management: definitions and standards for expedited reporting ICH Harmonised Tripartite Guideline. Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 27 October 1994 [Internet] [cited 2014 Dec 16]. Available from: http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2A\/Step4\/E2A_Guideline.pdf"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev: CD006924, 2013.","DOI":"10.1002\/14651858.CD006924.pub3"},{"key":"18","unstructured":"18. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephrits Work Group. KDIGO clinical practice guideline forglomerulonephrits. Kidney Int Suppl 2: 172-185, 2012."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-incipient minimal change nephritic syndrome: a long-term follow-up. Kidney Int 29: 1215-1223, 1986.","DOI":"10.1038\/ki.1986.130"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Grimbert P, Audard V, Remy P, Lang P, Sahali D. Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. Nephrol Dial Transplant 18: 245-248, 2003.","DOI":"10.1093\/ndt\/18.2.245"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Doublier S, Ruotsalainen V, Salvidio G, et al. Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathology 29: 1723-1731, 2001.","DOI":"10.1016\/S0002-9440(10)64128-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Furness PN, Hall LL, Shaw JA, Pringle JH. Glomerular expression of nephrin is decreased in acquired human nephrotic syndrome. Nephrol Dial Transplant 14: 1234-1237, 1999.","DOI":"10.1093\/ndt\/14.5.1234"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Wernerson A, Dun&eacute;r F, Pettersson E, et al. Altered ultrastructural distribution of nephrin in minimal change nephrotic syndrome. Nephrol Dial Transplant 18: 70-76, 2003.","DOI":"10.1093\/ndt\/18.1.70"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14: 931-938, 2008.","DOI":"10.1038\/nm.1857"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Xing CY, Saleem MA, Coward RJ, Ni L, Witherden IR, Mathieson PW. Direct effects of dexamethasone on human podocytes. Kidney Int 70: 1038-1045, 2006.","DOI":"10.1038\/sj.ki.5001655"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mak SK, Short CD, Mallick NP. Long-term outcome of adult-onset minimal-change nephropathy. Nephrol Dial Transplant 11: 2192-2201, 1996.","DOI":"10.1093\/oxfordjournals.ndt.a027136"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Fujimoto S, Yamamoto Y, Hisanaga S, Morita S, Eto T, Tanaka K. Minimal change nephrotic syndrome in adults: Response to corticocorticosteroid therapy and frequency of relapse. Am J Kidney Dis 17: 687-692, 1991.","DOI":"10.1016\/S0272-6386(12)80353-2"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43: 1801-1808, 2000.","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O"},{"key":"29","unstructured":"29. Elixhauser A, Owens P; for the Agency for Healthcare Research and Quality. Adverse Drug Events in U.S. Hospitals, 2004. Fraser I, Ed. Agency for Healthcare Research and Quality, Rockville, Md, 2007."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Shah M, Chaudhari S, McLaughlin TP, et al. Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus. Clin Ther 35: 486-497, 2013.","DOI":"10.1016\/j.clinthera.2013.03.001"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Shinzawa M, Yamamoto R, Nagasawa Y, et al. Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort study. Clin Exp Nephrol 17: 839-847, 2013.","DOI":"10.1007\/s10157-013-0793-9"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Huang JJ, Hsu SC, Chen FF, Sung JM, Tseng CC, Wang MC. Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis. Am J Nephrol 21: 28-34, 2001.","DOI":"10.1159\/000046215"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Tse KC, Lam MF, Yip PS, et al. Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. Nephrol Dial Transplant 18: 1316-1320, 2003.","DOI":"10.1093\/ndt\/gfg134"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kranz B, Vester U, B&uuml;scher R, Wingen AM, Hoyer PF. Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years. Pediatr Nephrol 23: 581-586, 2008.","DOI":"10.1007\/s00467-007-0709-6"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kim JH, Park SJ, Yoon SJ, et al. Predictive factors for ciclosporin-associated nephrotoxicity in children with minimal change nephrotic syndrome. J Clin Pathol 64: 516-519, 2011.","DOI":"10.1136\/jclinpath-2011-200005"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/17\/54_54.3927\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T21:26:48Z","timestamp":1567114008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/17\/54_54.3927\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":35,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.3927","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}